(Albany, US) DelveInsight has launched a new report on Thrombotic Thrombocytopenic Purpura Epidemiology
DelveInsight’s ‘Thrombotic Thrombocytopenic Purpura – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Thrombotic Thrombocytopenic Purpura epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia with profound thrombocytopenia. TTP is characterized by severe deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor (vWf)-cleaving protease. The ADAMTS13 gene provides instructions for enzyme production that are involved in the normal process of blood clotting. Normally, cleavage of vWF multimers by ADAMTS13 limits platelet binding to vWF. Mutations in this gene lead to a severe reduction in the activity of this enzyme leading to thrombocytopenia.
View Free Sample Page:- https://www.delveinsight.com/sample-request/thrombotic-thrombocytopenic-purpura-epidemiology-forecast
Thrombotic Thrombocytopenic Purpura Epidemiology
As per the National Organization for Rare Disorders (NORD), the current rate of TTP occurrence is about 3.7 cases per million people each year; with, two-thirds of individuals being women. The acquired TTP is a life-threatening ultra-orphan disease with an annual incidence between 1.5 and 6.0 cases per million in Europe (Miesbach et al.). The Inherited form of TTP results from mutations in ADAMTS13, and results in severe absence of the ADAMTS13 enzyme activity; there are more than 100 different causative ADAMTS13 mutations that have been identified, including missense (~62%), nonsense (~12.5%), splice site (~8%), and frame shift (deletions or insertions; ~17.5%) mutations, spreading over all ADAMTS13 protein-coding domains. However, people with the Acquired form do not have mutations in the ADAMTS13 gene. Instead, their immune systems often produce specific autoantibodies that block the activity of the ADAMTS13 enzyme. Anti-ADAMTS13 antibodies can be functional inhibitors or increase the enzyme clearance. Both ADAMTS13 activity, anti-ADAMTS13 autoantibodies assays can guide management options in TTP.
Key facts of the report
Thrombotic Thrombocytopenic Purpura Report Scope
Download free sample page:- https://www.delveinsight.com/sample-request/thrombotic-thrombocytopenic-purpura-epidemiology-forecast
Table of content
1. Key Insights
2. Executive Summary of Thrombotic Thrombocytopenic Purpura
3. Thrombotic Thrombocytopenic Purpura: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/